Dianosic raises €4.7M to bring treatment for chronic rhinitis into clinical trial

Latest round of capital and non-dilutive funding will enable Dianosic to complete preclinical in vivo testing and to launch phase I clinical trial of ARIS-R solution for chronic rhinitis

Strasbourg, France – February 6, 2023 – Dianosic, a deeptech company specializing in the development of innovative solutions for the treatment of Ear, Nose and Throat (ENT) conditions, today announces that it has closed a €4.7 million ($5.1M) funding round with historical investors, new private investors, Wiseed (crowdfunding), Fondation Force – a non-profit organization dedicated to innovation and healthcare research (scientific board presided over by Prof. Jules Hoffmann, winner of the Nobel Prize in Medicine in 2011) – and Bpifrance’s deeptech (non-dilutive funds). 

 
This funding will enable Dianosic to finance its preclinical in vivo study and launch the phase I clinical trial of its ARIS-R (Active Resorbable Intranasal Scaffold – Rhinitis) solution for the treatment of chronic allergic rhinitis. In parallel, the company will also continue to develop treatment options for chronic sinusitis (with its ARIS-S solution) and explore other potential applications in the field of ENT. Additionally, the new funding will be used to enhance the technical capability of the Dianosic team.
 
More than 250 million people across Europe and the US are affected by chronic rhinitis and sinusitis, and these numbers continue to increase as we see the impact of rising pollution levels and global warming. The European and US market is currently worth more than 25 billion dollars.[1]

Faced with these statistics, Marc Augustin, Philippe Bastide and Prof. Christian Debry joined forces in 2017 to create Dianosic. Their aim was to use their innovative ARIS platform to develop disruptive solutions for debilitating ENT conditions such as chronic rhinitis and sinusitis.
 
The ARIS platform is a novel technology combining a resorbable polymer insert with an active ingredient. As the insert starts to resorb, it releases a low dose of a corticosteroid in a targeted and steady manner over a period of six to twelve months. As a single administration treatment, ARIS has the potential to resolve patient compliance challenges and to improve the care of people around the world whose quality of life is severely disrupted by these chronic conditions.
 
“This new round of funding underlines the breakthrough nature of our platform. Our ultimate hope is that this device will secure Dianosic’s place as a leader in the treatment of debilitating ENT pathologies,” said Marc Augustin, president of Dianosic. “We would like to thank all our investors, both new and long-standing, for the confidence they have shown in our technology, our vision, the company founders and the entire Dianosic team.”
 
“We can’t wait to get the phase I clinical trial for ARIS-R underway and are convinced that it will considerably improve the care we offer patients living with chronic rhinitis. ENT specialists have been keenly anticipating this innovative treatment option, which is simple to administer in-office by ENT physicians. It has the much-needed potential to vastly improve the care available for patients with a condition that is currently very costly,” said Prof. Christian Debry, co-founder of Dianosic and head of the ENT – Head & Neck Surgery Department at Strasbourg University Hospital, France.
 
“The first-line treatments for chronic rhinitis, such as antihistamines and/or corticosteroid sprays, are not effective in 30% of cases. What’s more, only around 50% of patients take them as prescribed. Where medications fail, the only other options available are invasive treatments such as cryotherapy, radiofrequency or surgery. For patients where other treatments are not working, ARIS-R provides a long-term solution with a guaranteed compliance, which will preserve their quality of life,” said Philippe Bastide, CEO of Dianosic. “We also plan to use our research to develop treatments for other indications, notably sudden deafness, chronic facial pain and chronic migraines.”
 
Dianosic is also the company behind the CE-marked and FDA-registered CAVI-T medical device, an asymmetrical intranasal balloon designed to stop spontaneous or post-operative bleeding with low pressure compression. This device has been commercially available in Europe and the Middle East since 2021.
 
Legal adviser: MCE Carrel (Vincent Baudouin, Alexandra Carrel)
Financial adviser: Grant Thornton (Gilles Hoareau, Diane Verduen)
 
About Dianosic SAS
Dianosic specializes in the development of innovative treatment solutions for debilitating ENT conditions. Founded in July 2017, the Strasbourg-based company aims to become a world leader in the ENT field with its novel ARIS platform, which combines resorbable polymer inserts and medication.
The company was co-incubated by SEMIA and Quest for health – the healthcare accelerator for the Grand Est region in France. Both are rated as ‘incubators of excellence’. It is also supported by the wider Grand Est ecosystem, SATT Conectus, Bpifrance Alsace, Biovalley France, the Eurometropolis of Strasbourg, the Caisse d’Epargne Grand Est Europe and the Banque Populaire Rives de Paris.
Dianosic is managed by two of its co-founders, company president Marc Augustin and CEO Philippe Bastide. Prof. Christian Debry, the third co-founder and head of the ENT – Head & Neck Surgery Department at Strasbourg University Hospital, acts as a scientific advisor to the company. Dianosic has 13 employees and has raised a total of €6.2 million ($.6.7M) in capital and non-dilutive funding since its inception.
www.dianosic.com

[1]https://www.adroitmarketresearch.com/industry-reports/sinusitis-treatment-drugs-market
https://www.ihealthcareanalyst.com/global-sinus-dilation-devices-market/